Clinical trial D5164C00001 ADAURA
A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
| Cancers | |
|---|---|
| Organ | NSCLC |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2015-000662-65 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02511106 |
| Inclusion criteria | EGFR mutation : Ex19del, L858R, alone or in combination with T790M mutation. |
| Last update |